6
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Mapping the causal associations of cytokines with sarcopenia and aging traits: Evidence from bidirectional Mendelian randomization

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Cytokines and growth factors may serve as a bridge in studying the causal relationships between inflammaging and sarcopenia due to their roles in inflammaging. In this study, we aim to explore the causal association of cytokines with sarcopenia and aging traits and further identify the significant inflammation factors.

          Methods

          Bidirectional Mendelian randomization (MR) analysis was used to identify the causality. Forty‐one kinds of circulation cytokines and growth factors were set as exposures, and the data were from a summary genome‐wide association study (GWAS) containing three cohorts with 8293 healthy participants of European ancestry from 1983 to 2011. Hand grip strength, adjusted appendicular lean mass (AALM), usual walking pace, moderate‐to‐vigorous physical activity (MVPA) levels, able to walk or cycle unaided for 10 min (AWCU10) and telomere length were selected as outcomes. Data for outcomes were obtained from meta‐GWAS and the UK Biobank, and sample sizes ranged from 69 537 to 472 174. Low hand grip strength was defined by the European Working Group on Sarcopenia in Older People (EWGSOP) and Foundation for the National Institutes of Health (FNIH) cut‐off points, respectively. Other outcome traits were defined and measured according to the UK Biobank and raw cohorts' criteria. We set two significance thresholds for single nucleotide polymorphisms (SNPs) associated with exposures to obtain adequate SNPs (5 × 10 −6 and 5 × 10 −8). Inverse‐variance weighted, MR‐Egger and weighted median were employed to estimate the causality.

          Results

          Twenty‐seven factors were identified to relate to sarcopenia and aging traits causally, and most were associated with only one outcome trait. IL16 (interleukin‐16), CTACK (cutaneous T‐cell attracting chemokine), MIP1b (macrophage inflammatory protein 1b) and PDGFbb (platelet‐derived growth factor BB) were proven to relate causally to at least one sarcopenia and aging trait in both analyses with two significance thresholds. IL16 was causally associated with hand grip strength (0.977 [0.956–0.998] for EWGSOP and 0.933 [0.874–0.996] for FNIH), AALM (0.991 [0.984, 0.998]), MVPA (0.997 [0.995–1.000]) and AWCU10 (1.008 [1.003–1.013]). CTACK was proven to relate causally to hand grip strength (1.013 [1.007–1.019] for EWGSOP and 1.090 [1.041–1.142] for FNIH), AWCU10 (0.990 [0.986–0.994]) and telomere length (0.998 [0.983–0.994]). The results indicated that MIP1b has a causal effect on hand grip strength (1.032 [1.001–1.063] for EWGSOP), AWCU10 (0.994 [0.988–1.000] and 0.993 [0.988–0.998]) and telomere length (1.006 [1.000–1.012]). PDGFbb may causally relate to AALM (1.016 [1.001–1.030]) and telomere length (1.011 [1.007–1.015]). Reserve MR analyses also proved their unidirectional causal effects.

          Conclusions

          Twenty‐seven factors were causally related to sarcopenia and aging traits, and the causal effects of IL16, CTACK, MIP1b and PDGFbb were proven in both analyses with two significance thresholds.

          Related collections

          Most cited references39

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Sarcopenia: revised European consensus on definition and diagnosis

          Abstract Background in 2010, the European Working Group on Sarcopenia in Older People (EWGSOP) published a sarcopenia definition that aimed to foster advances in identifying and caring for people with sarcopenia. In early 2018, the Working Group met again (EWGSOP2) to update the original definition in order to reflect scientific and clinical evidence that has built over the last decade. This paper presents our updated findings. Objectives to increase consistency of research design, clinical diagnoses and ultimately, care for people with sarcopenia. Recommendations sarcopenia is a muscle disease (muscle failure) rooted in adverse muscle changes that accrue across a lifetime; sarcopenia is common among adults of older age but can also occur earlier in life. In this updated consensus paper on sarcopenia, EWGSOP2: (1) focuses on low muscle strength as a key characteristic of sarcopenia, uses detection of low muscle quantity and quality to confirm the sarcopenia diagnosis, and identifies poor physical performance as indicative of severe sarcopenia; (2) updates the clinical algorithm that can be used for sarcopenia case-finding, diagnosis and confirmation, and severity determination and (3) provides clear cut-off points for measurements of variables that identify and characterise sarcopenia. Conclusions EWGSOP2's updated recommendations aim to increase awareness of sarcopenia and its risk. With these new recommendations, EWGSOP2 calls for healthcare professionals who treat patients at risk for sarcopenia to take actions that will promote early detection and treatment. We also encourage more research in the field of sarcopenia in order to prevent or delay adverse health outcomes that incur a heavy burden for patients and healthcare systems.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty

            Most older individuals develop inflammageing, a condition characterized by elevated levels of blood inflammatory markers that carries high susceptibility to chronic morbidity, disability, frailty, and premature death. Potential mechanisms of inflammageing include genetic susceptibility, central obesity, increased gut permeability, changes to microbiota composition, cellular senescence, NLRP3 inflammasome activation, oxidative stress caused by dysfunctional mitochondria, immune cell dysregulation, and chronic infections. Inflammageing is a risk factor for cardiovascular diseases (CVDs), and clinical trials suggest that this association is causal. Inflammageing is also a risk factor for chronic kidney disease, diabetes mellitus, cancer, depression, dementia, and sarcopenia, but whether modulating inflammation beneficially affects the clinical course of non-CVD health problems is controversial. This uncertainty is an important issue to address because older patients with CVD are often affected by multimorbidity and frailty - which affect clinical manifestations, prognosis, and response to treatment - and are associated with inflammation by mechanisms similar to those in CVD. The hypothesis that inflammation affects CVD, multimorbidity, and frailty by inhibiting growth factors, increasing catabolism, and interfering with homeostatic signalling is supported by mechanistic studies but requires confirmation in humans. Whether early modulation of inflammageing prevents or delays the onset of cardiovascular frailty should be tested in clinical trials.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              PhenoScanner V2: an expanded tool for searching human genotype–phenotype associations

              Abstract Summary PhenoScanner is a curated database of publicly available results from large-scale genetic association studies in humans. This online tool facilitates ‘phenome scans’, where genetic variants are cross-referenced for association with many phenotypes of different types. Here we present a major update of PhenoScanner (‘PhenoScanner V2’), including over 150 million genetic variants and more than 65 billion associations (compared to 350 million associations in PhenoScanner V1) with diseases and traits, gene expression, metabolite and protein levels, and epigenetic markers. The query options have been extended to include searches by genes, genomic regions and phenotypes, as well as for genetic variants. All variants are positionally annotated using the Variant Effect Predictor and the phenotypes are mapped to Experimental Factor Ontology terms. Linkage disequilibrium statistics from the 1000 Genomes project can be used to search for phenotype associations with proxy variants. Availability and implementation PhenoScanner V2 is available at www.phenoscanner.medschl.cam.ac.uk.
                Bookmark

                Author and article information

                Contributors
                sunguixin@tongji.edu.cn , 64605610@qq.com
                sunguixin@tongji.edu.cn
                Journal
                J Cachexia Sarcopenia Muscle
                J Cachexia Sarcopenia Muscle
                10.1007/13539.2190-6009
                JCSM
                Journal of Cachexia, Sarcopenia and Muscle
                John Wiley and Sons Inc. (Hoboken )
                2190-5991
                2190-6009
                31 March 2024
                June 2024
                : 15
                : 3 ( doiID: 10.1002/jcsm.v15.3 )
                : 1121-1133
                Affiliations
                [ 1 ] Department of Traumatic Surgery, Shanghai East Hospital, School of Medicine Tongji University Shanghai China
                Author notes
                [*] [* ] Correspondence to: Guixin Sun and Chensong Yang, Department of Traumatic Surgery, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai 200092, China. Email: sunguixin@ 123456tongji.edu.cn and 64605610@ 123456qq.com

                Article
                JCSM13456 JCSM-D-23-00770
                10.1002/jcsm.13456
                11154762
                38556722
                3bbad28e-bb4d-4aed-af86-3ad01848f26a
                © 2024 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by Wiley Periodicals LLC.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

                History
                : 24 January 2024
                : 19 September 2023
                : 16 February 2024
                Page count
                Figures: 6, Tables: 0, Pages: 13, Words: 5990
                Funding
                Funded by: National Natural Science Foundation of China , doi 10.13039/501100001809;
                Award ID: 81971169
                Funded by: Leading Talents Training Program of Pudong New Area Health Commission
                Award ID: PWR 12020‐06
                Categories
                Original Article
                Original Articles
                Custom metadata
                2.0
                June 2024
                Converter:WILEY_ML3GV2_TO_JATSPMC version:6.4.4 mode:remove_FC converted:06.06.2024

                Orthopedics
                aging traits,cytokines,growth factors,sarcopenia
                Orthopedics
                aging traits, cytokines, growth factors, sarcopenia

                Comments

                Comment on this article